Bicara Therapeutics (BCAX) Capital Expenditures (2023 - 2026)
Bicara Therapeutics' (BCAX) quarterly Capital Expenditures came in at $60000.0 in Q1 2026, down 74.79% quarter-over-quarter from $238000.0 in Q4 2025.
Bicara Therapeutics (BCAX) Capital Expenditures (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Capital Expenditures history runs 4 years deep, the most recent figure standing at $60000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures changed N/A year-over-year to $60000.0 in Q1 2026; TTM through Mar 2026 was $340000.0, a 407.46% increase from a year earlier, with the FY2025 full-year figure at $280000.0, up 294.37% from the prior year.
- Capital Expenditures slipped to $60000.0 in Q1 2026 per BCAX's latest filing, from $238000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $436000.0 in Q4 2023 and bottomed at $4000.0 in Q1 2024.
- The 4-year median for Capital Expenditures is $41000.0 (2024), against an average of $105875.0.
- Across the five-year window, Capital Expenditures slumped 90.83% in 2024 and soared 495.0% in 2025, its largest moves.
- Year by year, Capital Expenditures stood at $436000.0 in 2023, then slumped by 90.83% to $40000.0 in 2024, then surged by 495.0% to $238000.0 in 2025, then sank by 74.79% to $60000.0 in 2026.
- Per Business Quant, the three latest BCAX Capital Expenditures figures stand at $60000.0 (Q1 2026), $238000.0 (Q4 2025), and $42000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 786,000.00 |
| 10 | Bicara Therapeutics | 1.64 Bn | 1.64 Bn | - | 60,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60,000.00 |
| Mar 31, 2026 | 60,000.00 |
| Dec 31, 2025 | 238,000.00 |
| Dec 31, 2025 | 238,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Dec 31, 2024 | 40,000.00 |
| Dec 31, 2024 | 40,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | 436,000.00 |
| Dec 31, 2023 | 436,000.00 |